Please use this identifier to cite or link to this item:
|Title:||Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy|
W. C. Hellinger
T. A. Gonwa
Mayo Clinic in Jacksonville, Florida
|Citation:||Transplant Infectious Disease. Vol.15, No.1 (2013)|
|Abstract:||Mycobacterium tuberculosis infection is one of many opportunistic infections in renal transplant recipients, arising either from reactivation of latent infection or de novo infection, occasionally donor derived. M. tuberculosis hepatitis has never been reported in patients who have received alemtuzumab as part of their renal transplant management. We describe 2 patients who underwent deceased-donor renal transplantation following alemtuzumab induction therapy and presented with a febrile syndrome, subsequently diagnosed as tuberculous hepatitis, one with disseminated disease. Both responded well to treatment without significant side effects, resulting in excellent graft function. The importance of chemoprophylaxis should be emphasized to minimize the risk of developing active tuberculosis in patients with latent tuberculosis infection undergoing solid organ transplantation. © 2012 John Wiley & Sons A/S.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.